Document:

Development Agreement with Scott D. Boden

 Exhibit 10.37 
  
 EXECUTION COPY 
  
 DEVELOPMENT AGREEMENT 
  
 This Development Agreement (this “Agreement”) is made and entered into as of the 21st day of July, 2005 (the “Effective Date”), by and
between AMEDICA CORP., a Delaware corporation (“Amedica”), and Scott D. Boden, M.D. (“Boden”). 
  
  
 RECITALS: 
  
 A. Amedica is in the business of designing, developing and selling various products and applications for medical and
biomedical uses that are made from various materials, including advanced ceramic materials. 
  
 B. Amedica desires to continue to encourage the development, testing and clinical training for novel Devices (as defined herein) for implant in or use with the spine in medical and surgical procedures, whether
manufactured from ceramic materials or other materials. 
  
 C.
Boden offers clinical knowledge and experience relating to the spine. 
  
 D. The parties desire to enter into an agreement to assist in the future development, approval, trial and clinical use of Devices. 
  
 E. Boden desires the right to assign to an entity controlled by Boden the rights and obligations of Boden hereunder. 
  
 NOW, THEREFORE, for and in consideration of the mutual promises and covenants
herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree and represent as follows: 
  
 1. Definitions. For purposes of this Agreement, the following terms shall have the following definitions:

  
 a. “Development Services” means the development and
related services as requested by Amedica relating to the conceptualization, development, testing, approval and related matters involving the Devices more fully described in Section 2, below. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. “Devices” means all ideas, discoveries, creations, improvements, know-how, inventions,
designs, developments, apparatus, techniques, methods, processes, and materials, whether or not patentable, including all rights to obtain, perfect or enforce any proprietary interests therein, in the Field of Interest, which Boden, whether alone or
in concert with others, may conceive, reduce to practice or develop during the Term (or, if based on or related to any confidential or proprietary information of Amedica, within [***********] after the termination of this Agreement), alone or
in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of Amedica, or otherwise. These Devices include but are not limited to those items more fully identified on
Schedule A attached hereto. 
  
 c. “Field of
Interest” means the development, testing and commercializing of biomedical or surgical devices, covered by current Amedica patent applications and further Amedica developments, including ceramic and metallic materials, intended for use in
diagnosing, preventing or treating diseases or conditions affecting the spine or related structure or tissues or any applications thereof. Amedica may expand or otherwise change the definition of its Field of Interest at any time, as long as this
expansion continues to be related solely to ceramic materials, which new definition will be binding upon Boden ten (10) days after written notice to Boden thereof 
  
 2. Development Arrangements. The parties intend that Boden shall diligently perform the Development Services
which shall include, without limitation, the following: 
  
 a.
Examining and reviewing the characteristics of the Devices and the nature of the materials with which the Devices are constructed. 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. Offering experience on ideas and testing pertaining to the Devices, and coordinating with other
Amedica personnel and third parties related to such testing, as requested by Amedica. 
  
 c. Providing guidance and assistance in the clinical details of the Devices. 
  
 d. Assisting in the filing of provisional patents and other patents pertaining to the Devices as determined by Amedica. 
  
 e. Assisting in applying for or otherwise seeking regulatory approval for the
Devices or surgical processes for their implantation or other use. 
  
 3. Performance by Entity. Amedica agrees and consents that Boden may assign to an entity Boden’s rights and obligations hereunder, provided that: 
  
 a. The entity shall be under Boden’s control; and the entity shall provide for the entity’s services to be
performed by Boden, except as otherwise agreed to by Amedica, which consent shall not be unreasonably withheld. 
  
 b. Boden shall continue to be personally subject to and bound by the provisions of Sections 7 through 11, inclusive, of this Agreement. 
  
 4. Term and Termination. 
  
 a. The term (the “Term”) of this Agreement shall commence as of
the Effective Date and shall continue until the later of: (i) ten (10) years from the date hereof; or (ii) the expiration of the final remaining patent rights on the last of the Devices, unless earlier terminated as provided
hereunder. 
  
 b. Either party has the right to terminate this
Agreement at any time upon thirty (30) days’ prior written notice thereof to the other party. If either party terminates this Agreement pursuant to this subsection 4(b), Amedica shall be obligated to continue to pay royalty payments that
are earned for Devices resulting from Boden’s Development Services as set forth in Section 5 below. 
  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 5. Compensation for Assignment and Sale Proprietary Rights. As full consideration for the
Development Services and any valuable assignment of rights in or related to Devices to Amedica pursuant to Section 8 hereof, Amedica shall pay Boden the total of the following: 
  
 a. Boden shall, in the form of royalty or similar payments, receive [***************] of the Net After-Tax Profits as
separately agreed upon by Boden and Amedica; provided, that this is subject to the provisions of Subsections 5(b) and 5(c) below. “Net After-Tax Profits” is defined as that portion of profits received by Amedica attributable to sale of
Devices, after deducting from all gross proceeds from such sales the costs and expenses attributable to the development, testing, marketing and sale of the Devices (but not including any Amedica overhead or expenses unrelated to the Devices), and
less all sales, use, occupation or excise taxes and all income taxes applicable to income generated from the Devices. 
  
 b. Upon Boden’s death, or upon letters from two independent physicians that Boden is permanently disabled and unable to perform the nature of the
Development Services hereunder, this Agreement shall terminate as to Boden; provided, that Boden (or Boden’s surviving spouse or estate), or Boden’s entity, as applicable, shall continue to be entitled to receive the royalties as provided
herein. 
  
 c. Notwithstanding any provision herein to the
contrary, income used for calculating royalties payable to Boden hereunder shall not include any sales attributable to the use of any Devices by any hospital or surgical center where Boden, or any entity controlled by Boden currently practices
medicine or contracts for services. 
  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 No provision under this Agreement, either overtly or covertly, directly or indirectly, requires or
contemplates that Boden make any recommendations to Boden’s patients or health care facilities with respect to Amedica’s Devices or other products. There shall be no adjustment to the percentage of royalties, or the rate of any other
compensation, if any, resulting from the presence of or absence of, any recommendations of Amedica’s Devices or other products to Boden’s patients or health care facilities by Boden. 
  
 If Boden is paid any share of Net After Tax Profits inconsistent with the
provisions of this Subsection 5(c), upon advance written notice to Boden, Amedica will offset such improperly paid amount from any future payment owing to Boden. 
  
 d. Amedica shall maintain separate and sufficient accountings and records relating to the Devices to enable the payments
payable hereunder to be determined and verified. Boden shall, at all times, have the right, during normal business hours and upon reasonable notice to Amedica, to audit on a confidential basis the relevant books and records of Amedica to verify that
the payments due and owing Boden pursuant to subsection 5(a) have been accurately determined. The costs of such audits shall be borne by Boden unless he has been underpaid by [***************]; in such case, costs of the audit shall be paid
by Amedica. Payment of any amount determined to be owing to Boden will be made to him in accordance with the provisions of Subsection 4(b) above. 
  
 e. Without limiting the provisions of Subsection 4(b), the parties acknowledge that the continued payment of, and the continuing obligation to pay, the
royalties payable hereunder is not dependent on the continuing performance of the Development Services, the ongoing Term of this Agreement, or any other contingency or condition. 
  
 f. Boden acknowledges that the payment provisions of this Section 5 

  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
represent the sole agreement between the parties with regard to Boden’s compensation for all Development Services and any assignment of rights to the
Devices; and Amedica shall not be obligated to make, or otherwise be liable for, any additional payment of compensation or reimbursement of expenses with regard to Development Services or the Devices or other similar type payment. It is the
parties’ intent that this Agreement provide for the “sale or exchange of a capital asset” by Boden to Amedica under Internal Revenue Code Section 1235 entitled “Sale or Exchange of Patents,” and that all payments made
to Boden hereunder shall be taxed as long-term capital gains. Nothing in this Agreement to the contrary shall imply that the parties intend that the payments to Boden hereunder shall be for anything other than the transfer of all proprietary rights
that Boden may have in the Devices. Amedica is making no warranties or representations, however, as to ultimate taxability of the payments to Boden hereunder. 
  

6. Exclusivity. Amedica acknowledges that Boden, and any entities which may currently or in the future be controlled by Boden, have other
professional business and investment dealings in addition to his responsibilities under this Agreement and that Boden will not be required to devote his time exclusively to his responsibilities hereunder, either directly or indirectly.
Notwithstanding any provision herein to the contrary, Boden agrees that during the Term, as between Boden and Amedica, Amedica shall possess the exclusive ownership of the Devices. Amedica acknowledges that this is a non-exclusive agreement, and
nothing herein may be construed to prohibit either Amedica or Boden from entering into similar contractual relationships with other parties, or from engaging or participating in any other venture, unrelated to the Devices. Without limiting the
foregoing, Amedica recognizes and acknowledges that Boden (either directly or though his entities) actively performs product development services for and on other parties in the area of orthopedic surgery and related fields; therefore, Boden may

  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
provide consulting, product development, and other services, not related to the Devices, for and on behalf of persons or entities that may compete with
Amedica or that develop, manufacture, or sell products or technologies that are similar in function or design (excluding the Field of Interest) to those developed or sold by Amedica. 
  
 7. Confidentiality. 
  

a. Both during the Term and following termination of this Agreement for any reason, except as necessary for the performance of the Development Services
hereunder, Boden shall not, at any time or in any manner, directly or indirectly, use, divulge, disclose or communicate to any third-person or entity any information that was disclosed to or developed by Boden during the course of performing the
Development Services and which is not (i) information that Boden was aware of prior to the term of this Agreement, (ii) information that Boden becomes aware of through a source other than Amedica, (iii) information that is available
to the general public through a prior disclosure, provided that Boden did not commit such prior disclosure in violation of this Agreement, or (iv) the Retained Intellectual Property (as defined herein). Also without limiting the foregoing,
Boden may disclose the existence and general nature of this Agreement and the fact that it pertains to the Development Services and the Devices. Subject to the foregoing exceptions, the confidential information described herein shall include
information regarding matters affecting or relating to Amedica’s business or its Devices; the nature of Amedica’s properties or products, whether developed or under development; the identity of Amedica’s customers; prices which
Amedica obtains or has obtained with respect to its products or services; information as to Amedica’s discussions, negotiations and/or dealings with actual or potential third-party buyers, investors, licensees or co-venturers; Amedica’s
costs, overhead or profit margin; or Amedica’s operational methods or its business plans and processes. 
  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. Promptly following termination of this Agreement, Boden shall deliver to Amedica any and all property
of Amedica which may be in his possession including products, materials, memoranda, notes, records, reports, writings, drawings, diskettes, models and other materials or other documents or photocopies of the same in any tangible form whatsoever
constituting confidential or proprietary information of Amedica, and any of the foregoing in intangible form. 
  
 8. Covenant Not to Compete. 
  
 a. Boden recognizes and acknowledges the competitive and proprietary nature of Amedica’s Field of Interest. Boden acknowledges and agrees that a
business will be deemed competitive with Amedica if it develops, manufactures or sells any products within the Field of Interest and Boden has participated in the creation, research and/or testing of those such products (such business to be referred
to as a “Competitive Business”). 
  
 b. Boden agrees
that during the Term and for an additional [**********] after termination of this Agreement (which period shall be tolled during the period of any violation or breach of any of the provisions of this Section 8 and for a period of
[**********] thereafter), Boden shall not: 
  
 (i) for his benefit, or on behalf of any other person or entity, directly or indirectly, as principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, or be concerned,
connected or employed by, or otherwise associate in any manner with, engage in or have a financial interest in any Competitive Business anywhere in the continental United States of America (the “Restricted Territory”), except that nothing
contained herein shall preclude 

  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Boden from purchasing or owning securities of any such business if such securities are publicly traded, and provided that his holdings do not exceed one
percent (1%) of the issued and outstanding securities of any class of securities of such business; or 
  
 (ii) either individually or on behalf of or through any third party, directly or indirectly, solicit, entice or persuade or attempt to
solicit, entice or persuade any other employees of or consultants to Amedica or any present or future parent, subsidiary or affiliate of Amedica to leave the services of Amedica or any such parent, subsidiary or affiliate for any reason. 

 
 c. Boden further recognizes and acknowledges that: (i) the
restrictions in this Section 8 are reasonable in relation to the skills which represent his principal salable asset both to Amedica and to any prospective employers, and (ii) the geographical scope of the provisions of this Section 8
is reasonable, legitimate and fair to Boden in light of Amedica’s need to market its services and sell its products worldwide in order to have a sufficient customer base to make Amedica’s business profitable and in light of the limited
restrictions on the type of employment prohibited herein compared to the types of employment for which Boden is qualified to earn his livelihood. 
  
 d. Notwithstanding anything herein to the contrary, nothing in this Section 8 shall apply with regard to any services performed by Boden prior to the
Term hereof (and which services do not involve any activities by Boden within the Field of Interest continuing from and after the date of this Agreement) with regard to any devices, ideas, discoveries, creations, improvements, know-how, inventions,
designs, developments, apparatus, techniques, methods, processes, and materials of any kind (the “Prior Work”). Accordingly, nothing herein shall prohibit Boden’s receipt of any compensation of any kind (e.g., royalties) in
consideration for such Prior Work. 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. The acknowledgments and agreements set forth in this Section 8 shall survive the termination of
Boden’s performance of the Development Services for any reason, for the time period set forth herein. 
  
 9. Ownership of Ideas, Copyrights and Patents. 
  
 a. Boden agrees that he will take reasonable steps to promptly disclose all Devices to Amedica and that he will not publish any Devices, or any
information with regard thereto, without the prior written consent of Amedica, which will not be unreasonably withheld. 
  
 b. As between Boden and Amedica, Amedica shall have the sole and exclusive right, even as to Boden, to prepare, file, prosecute, obtain and maintain any
and all patents and patent applications claiming any Devices. All Devices shall be the sole and exclusive property of Amedica and, subject to payment pursuant to the provisions of Section 3 hereof, and the waivers of any and all representations
and warranties concerning the Devices as set forth in Subsection 10(e) below, Boden hereby assigns to Amedica all of his right, title and interest in and to all of the Devices, including the intellectual property therein, which may include trade
secrets, inventions, discoveries, or improvements, whether or not registerable or patentable, that are conceived, whether alone or jointly with others, during the Term of this Agreement that are a direct and specific result of the Development
Services (collectively, the “Assigned Intellectual Property). This assignment does not include any such intellectual property that pertains to (i) orthopedic surgical principles in general (including products that may pertain to the same
pathological conditions in the same anatomical locations that are relevant to the Devices; to (ii) other products or technologies used in orthopedic surgery; (iii) to proprietary concepts and inventions in which Boden has any right, title,
or interest as of the date 

  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
of the execution of this Agreement (collectively “Prior Rights”), or (iv) to any other concept, know-how, discovery, or other intellectual
property that is not within the definition of the Assigned Intellectual Property (all of the foregoing collectively, the “Retained Intellectual Property”). Boden shall not be restricted from assigning, licensing, or otherwise utilizing the
Retained Intellectual Property in any manner. 
  
 c. Boden hereby
agrees to reasonably cooperate with Amedica, its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect Amedica’s rights in and to any Devices, including, but not limited to,
performing all acts reasonably deemed necessary or desirable by Amedica (both during the Term and for a period of [***********] after expiration of this Agreement) and joining in any proceeding to obtain letters patent, copyrights, trademarks
or other legal rights of the United States of America and of any and all other countries to Devices; provided, that, Amedica will bear the expense of all such proceedings. Boden hereby agrees that any patent or other legal right covering any
Assigned Intellectual Property issued to Boden, shall be assigned by Boden to Amedica without charge. 
  
 d. Without limiting the foregoing, Boden further acknowledges that all original works of authorship made by such Boden, within the Field of Interest, by
Boden that Boden has first conceived and first reduced to writing, whether alone or jointly with others during the Term of this Agreement that are a direct and specific result of the Development Services and that are protectable by copyright are
“works made for hire” within the meaning of the United States Copyright Act, 17 U.S.C. § 101, as amended, the copyright of which shall be owned solely, completely and exclusively by Amedica. If any such work is not considered to be a
work made for hire covered by the United States Copyright Act, 17 U.S.C. § 101, as amended, such work shall be owned solely by, or hereby assigned or transferred completely and exclusively to, Amedica. Any and all works of authorship described
in this Subsection shall be included within the definition of Assigned Intellectual Property. 
  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Notwithstanding anything herein to the contrary, Boden expressly disclaims, and Amedica expressly
waives, any and all representations and warranties in regard to or concerning the Assigned Intellectual Property, the Development Services and the Devices. Without limiting the foregoing, the parties agree that Boden does not represent or warrant
that any portion of the Assigned Intellectual Property is valid, enforceable, registerable, or original, that it will be free from claims of infringement, interference, or unlawful use of proprietary information of any third party, or that it does
not infringe upon the intellectual property rights of any other party. Furthermore, Boden expressly disclaims, and Amedica expressly waives, the warranties of merchantability and fitness for a particular purpose with regard to the Assigned
Intellectual Property, the Development Services and the Devices, and any and all representations and warranties that the Assigned Intellectual Property and the Devices will perform or function in any particular manner, with any particular results,
or free from defects. 
  
 10. Representations and Warranties
Regarding Prior Work and Legal Obligations. 
  
 a. Boden
hereby represents and warrants that he has no commitments or obligations with any prior employer or any other person or entity that, would restrict his ability to perform the Development Services. 
  
 b. Boden represents that he has been advised by Amedica that at no time
should he divulge to, or use for the benefit of, Amedica any trade secret or confidential or proprietary information of any previous employer. Boden acknowledges that he has not divulged or used any such information for the benefit of Amedica.

  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 c. Boden acknowledges that Amedica is basing important business decisions on these representations, and
affirms that all of the statements included herein are true. 
  
 11. Equitable Remedies. Boden acknowledges that the breach of the provisions of Sections 7, 8, 9 and 10 above shall constitute irreparable damage to Amedica and, accordingly, Amedica may, in addition to all other available
remedies under law and equity, obtain injunctive relief upon an alleged violation of such Sections pending resolution on the merits of any claims raised by Amedica hereunder. 
  
 12. Stock Option Arrangements. As further consideration hereunder, the parties agree in good faith to
negotiate an agreement granting Boden, or Boden’s designate, certain rights to obtain options for the purchase of Amedica stock. The nature, amount and terms of such options shall be agreed upon by the parties in good-faith as soon as
reasonably possible. 
  
 13. Development Agreement
Only. This Agreement constitutes a development agreement only. Nothing herein is intended, nor shall it be construed, to create any employer/employee arrangement, partnership arrangement or other relationship between or among the parties
except as expressly provided herein; and nothing herein is intended to grant to either party any right or interest in or to the assets, business or interests of the other party, nor the right to bind the other party except as expressly herein
provided. 
  
 14. Compliance with Laws and
Regulations. The parties, at all times, shall interpret and apply the provisions of this Agreement strictly in accordance with all applicable laws and regulations, including, but not limited to all Medicare and Medicaid laws and regulations.

  
 a. If any provision of this Agreement is found, by any
applicable court or government agency, to be in conflict with any applicable law or regulation, the provisions of such law or regulation shall govern; and the interpretation and operation under this Agreement shall be modified accordingly.

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. The parties have no intent through this Agreement or otherwise to solicit, receive, offer, or pay any
remuneration in return for recommending the use or utilization of any good or service payable under certain federal health programs, as such is prohibited by the statute at 42 U.S.C. 1320a-7b(b), nor do the parties have any other impermissible
intent to violate any similar federal or state law that may apply with regard to any other health care reimbursement program. Boden is under no obligation whatsoever to utilize any products manufactured by Amedica, nor to recommend that such
products are utilized by others. If any provision of this Agreement is determined by either party to present a possible violation of any such law, as supported by a written, reasoned opinion of competent legal counsel, the parties shall in good
faith negotiate together to amend the terms of this Agreement in a manner that will alleviate any such possible violation while preserving the reasonable business (e.g., compensation) expectations of the parties. 
  
 15. Indemnification by Amedica. 
  
 a. Amedica will indemnify and hold Boden harmless from any and all claims,
costs, judgments and expenses (including reasonable attorneys fees) involving (i) any claim that any Device infringes or interferes with any patent or other proprietary claim of any third-party, and (ii) to the extent claimed or proven to
be solely due to Device design or manufacturing defect of whatever sort based on claims of product design or manufacturing defects whether sounding in negligence, strict liability at law, contract or statutory violation, and (iii) any breach by
Amedica of any provision of this Agreement. 
  
 b. Any
indemnification provided by Amedica hereunder shall not apply to 

  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
any claim insofar as that claim (i) relates to a professional medical liability or malpractice claim brought against Boden for professional acts or
omissions in connection with the medical care or treatment associated with a Device; (ii) arises from any breach by Boden of any provision of this Agreements; or (iii) arises from any knowing submission by Boden of false data to Amedica or
from any other intentional wrongdoing by Boden. 
  
 c. Promptly
upon Boden’s receipt of information concerning the commencement of any third-party claim, demand, action, suit or proceeding (collectively, “Action”) which is the subject of indemnification hereunder, Boden shall notify Amedica in
writing of the commencement of the Action. Any failure to provide such prompt notice shall relieve Amedica of its indemnification obligations to the extent Amedica has been materially prejudiced by such failure. Amedica may select counsel at its own
expense and control the defense of such indemnity claim; and Boden may participate jointly with Amedica in such defense, at Boden’s expense, in which event the parties shall reasonably cooperate with each other. Amedica will vigorously defend
any such claim, and shall not settle any such claim or refrain from appealing any adverse ruling, judgment, or verdict without the advance written consent of Boden, which consent shall not be unreasonably withheld. With respect to any Action
relating solely to the payment of money damages, Amedica shall have the sole right to defend, settle, or otherwise dispose of such claim on such terms as Amedica, in its sole discretion, shall deem appropriate; provided, that Amedica shall provide
reasonable evidence of its ability to pay any damages claimed. If the Action involves any claim in which Boden would become subject to injunctive relief or to other equitable relief, or Boden’s business would be adversely affected in any
manner, Amedica shall settle that claim only upon the written consent of Boden, which shall not be unreasonably withheld. 
  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 16. Indemnification by Boden. Except to the extent that any such claims arise through the
wrongful act or neglect of Amedica, Boden will indemnify and hold Amedica harmless from any and all claims, costs, judgments and expenses arising from any breach by Boden of any warranty, representation or affirmative obligation of Boden under this
Agreement. 
  
 17. General. 
  
 a. Notices. All notices required or permitted to be given to a party
hereunder shall be mailed by certified mail or registered mail, postage prepaid, to that party’s address set forth on the signature page of this Agreement (or to such other address specified in writing). 
  
 b. Default. If either party defaults in any of the covenants or
provisions herein, the defaulting party shall pay all costs and attorneys’ fees incurred by the other party in enforcing its rights arising hereunder. Boden’s counsel set forth below shall be provided with a copy of any notice given to
Boden hereunder: 
  

					
		  	  
	  	
		  	  
	  	
		  	  
	  	

  
 c. Governing Law
and Venue. This Agreement shall be interpreted, performed and enforced according to the laws of Utah. Venue for any action hereof shall lie with the Third Judicial District Court of the State of Utah for the United States District Court for the
District of Utah, Central Division. 
  
 d. Unenforceable
Provision. If any provision of this Agreement is deemed unenforceable by any court of competent jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be over broad
as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and shall be enforced as amended. 
  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Assignment. Amedica may assign its rights and obligations hereunder to any person or entity
that succeeds to all or substantially all of Amedica’s business or that aspect of Amedica’s business in which Boden is principally involved. Boden’s rights and obligations under this Agreement may not be assigned by Boden without the
prior written consent of Amedica except for the right to receive payments pursuant to Section 5 above. 
  
 f. Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and
shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except between the parties hereto, and no person or entity shall be
regarded as a third-party beneficiary of this Agreement, other than any future parent, subsidiary or affiliate of Amedica. 
  
 g. Entire Agreement. This Agreement embodies the entire agreement and understanding between and among the parties hereto with respect to the
subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement
shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 
  
 h. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the
parties hereto. 
  
 i. Waivers and Consents. The terms and
provisions of this Agreement may 

  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or
provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the
specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 
  
 j. Construction. The parties have participated equally in the formation of this Agreement and the language of this Agreement will not be
presumptively construed against either party. 
  
 k.
Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 
  
 l. Section Numbers and Headings. The
Section and Subsection headings and numbers used herein are for purposes of convenience and shall not be considered in the interpretation of this Agreement. 
  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF this 25th day of January, 2006. 
  

					
	 	 	 	  	AMEDICA
			
	ADDRESS:	 	 	  	AMEDICA CORP.
		 		  	A DELAWARE CORPORATION
			
		 		  	
			
	Amedica Corporation	 		  	
			
	615 Arapeen Drive, Suite 302	 		  	 /s/ Eugene B. Jones

	Salt Lake City, UT 84108	 		  	Eugene B. Jones
		 		  	Vice President, Finance & CFO
			
		 		  	BODEN
			
	ADDRESS:	 		  	
			
	Scott D. Boden, M.D.	 		  	
	[********************]	 		  	 /s/ Scott D. Boden

	[********************]	 		  	Scott D. Boden, M.D.
			
	[********************]	 		  	
			
	[********************]	 		  	
			
	[********************]	 		  	

  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE A 
  
 Devices 
  
 The Devices consist of the following: 
  

	 	1.	 	[***************************************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.Development Agreement with Carl Lauryssen

 Exhibit 10.38 
  
 EXECUTION COPY 
  
 DEVELOPMENT AGREEMENT 
  
 This Development Agreement (this “Agreement”) is made and entered into as of the 8th day of August, 2005 (the “Effective Date”), by
and between AMEDICA CORP., a Delaware corporation (“Amedica”), and Carl Lauryssen, M.D. (“Lauryssen”). 
  
  
 RECITALS: 
  
 A. Amedica is in the business of designing, developing and selling various products and applications for medical and
biomedical uses that are made from various materials, including advanced ceramic materials. 
  
 B. Amedica desires to continue to encourage, through collaboration among two or more developers (“Collaborators”), the development, testing and clinical training for novel Devices (as defined herein) for
implant in or use with the spine in medical and surgical procedures, whether manufactured from ceramic materials or other materials. 
  
 C. Lauryssen offers clinical knowledge and experience relating to the spine. 
  
 D. The parties desire to enter into an agreement to assist in the future development, approval, trial and clinical use of
Devices. 
  
 E. Lauryssen desires the right to assign to an entity
controlled by Lauryssen the rights and obligations of Lauryssen hereunder. 
  
 NOW, THEREFORE, for and in consideration of the mutual promises and covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
agree and represent as follows: 
  
 1. Definitions.
For purposes of this Agreement, the following terms shall have the following definitions: 
  
 a. “Development Services” means the development and related services as requested by Amedica relating to the conceptualization,
development, testing, approval and related matters involving the Devices more fully described in Section 2, below. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. “Devices” means all ideas, discoveries, creations, improvements, know-how,
inventions, designs, developments, apparatus, techniques, methods, processes, and materials, whether or not patentable, including all rights to obtain, perfect or enforce any proprietary interests therein, in the Field of Interest, which Lauryssen,
whether alone or in concert with others, may conceive, reduce to practice or develop during the Term (or, if based on or related to any confidential or proprietary information of Amedica, within [***********] after the termination of this
Agreement), alone or in conjunction with another, or others, whether during or out of regular business hours, and whether at the request or upon the suggestion of Amedica, or otherwise. These Devices include but are not limited to those items more
fully identified on Schedule A attached hereto. 
  
 c. “Field of Interest” means the development, testing and commercializing of biomedical or surgical devices, covered by current Amedica patent applications and further Amedica developments, and utilizing ceramic materials,
intended for use in diagnosing, preventing or treating diseases or conditions affecting the spine or related structure or tissues or any applications thereof. Amedica may expand or otherwise change the definition of its Field of Interest at any
time, as long as this expansion continues to be related solely to ceramic materials, which new definition will be binding upon Lauryssen ten (10) days after written notice to Lauryssen thereof. 
  
 d. “Collaborators” refer to the list of
professionals more fully identified on Schedule B attached hereto. 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 2. Cooperative Development Arrangements. The parties intend that Lauryssen, in collaboration and
cooperation with the Collaborators shall diligently perform the Development Services which shall include, without limitation, the following 
  
 a. Examining and reviewing the characteristics of the Devices and the nature of the materials with which the Devices are constructed.

  
 b. Offering experience on ideas and testing
pertaining to the Devices, and coordinating with other Amedica personnel and third parties related to such testing, as requested by Amedica. 
  
 c. Providing guidance and assistance in the clinical details of the Devices. 
  
 d. Assisting in the filing of provisional patents and other
patents pertaining to the Devices as determined by Amedica. 
  
 e. Assisting in applying for or otherwise seeking regulatory approval for the Devices or surgical processes for their implantation or other use. 
  
 3. Performance by Entity. Amedica agrees and consents that Lauryssen may assign to an entity Lauryssen’s
rights and obligations hereunder, provided that: 
  
 a. The entity shall be under Lauryssen’s control; and the entity shall provide for the entity’s services to be performed by Lauryssen, except as otherwise agreed to by Amedica, which consent shall not be unreasonably withheld.

  
 b. Lauryssen shall continue to be personally
subject to and bound by the provisions of Sections 8 through 12, inclusive, of this Agreement. 
  
 4. Term and Termination. 
  
 a. The term (the “Term”) of this Agreement shall commence as of the Effective Date and shall continue until the later of: (i) ten (10) years from the date hereof; or (ii) the expiration of the
final remaining patent rights on the last of the Devices, unless earlier terminated as provided hereunder. 
  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 b. Either party has the right to terminate this Agreement at any time upon thirty
(30) days’ prior written notice thereof to the other party. If either party terminates this Agreement pursuant to this subsection 4(b), Amedica shall be obligated to continue to pay royalty payments that are earned for Devices resulting
from Lauryssen’s Development Services. 
  
 c. The parties acknowledge that Amedica has entered into agreements with other Collaborators, listed on Exhibit “B,” attached hereto, which agreements contain the same material provisions contained in this Agreement. Those other
agreements and this Agreement, which are intended to be performed in cooperation with each other, are referred to herein as the “Collaboration Agreements.” Upon the death or termination of a Collaborator other than Lauryssen (or
Lauryssen’s entity, as applicable) this Agreement shall continue (subject to Subsection 4(b) above) as to Lauryssen and all remaining Collaborator(s); provided, that Lauryssen agrees, as soon as reasonably possible, to negotiate in good faith
with the remaining Collaborators any modifications to Lauryssen’s duties and compensation as may be appropriate under the circumstances. 
  
 5. Compensation for Assignment and Sale Proprietary Rights. As full consideration for the Development Services and any valuable assignment
of rights in or related to Devices to Amedica pursuant to Section 9 hereof, Amedica shall pay Lauryssen the total of the following: 
  
 a. Lauryssen shall, in the form of royalty or similar payments, receive the total of up to [**************] of the Net After-Tax
Profits as separately agreed upon 

  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
by Lauryssen and Amedica; provided, that this is subject to the provisions of Subsections 5(c) and 5(d) below. “Net After-Tax Profits” is defined
as that portion of profits received by Amedica attributable to sale of Devices, after deducting from all gross proceeds from such sales the costs and expenses attributable to the development, testing, marketing and sale of the Devices (but not
including any Amedica overhead or expenses unrelated to the Devices), and less all sales, use, occupation or excise taxes and all income taxes applicable to income generated from the Devices. 
  
 b. Lauryssen’s respective share of the Net After-Tax
Profits may be modified by Lauryssen and Amedica, in good faith, based upon Lauryssen’s contribution to the final form of the Devices, relative to the contributions of Amedica, other Collaborators and any third parties. Such share shall be
calculated on a monthly basis, with payment to Lauryssen of each monthly amount no later than the last day of the following month. 
  
 c. Upon Lauryssen’s death, or upon letters from two independent physicians that Lauryssen is permanently disabled and unable to
perform the nature of the Development Services hereunder, this Agreement shall terminate as to Lauryssen; provided, that Lauryssen (or Lauryssen’s surviving spouse or estate), or Lauryssen’s entity, as applicable, shall continue to be
entitled to receive the royalties as provided herein. 
  
 d. Notwithstanding any provision herein to the contrary, income used for calculating royalties payable to Lauryssen hereunder shall not include any sales attributable to the use of any Devices by any hospital or surgical center where
Lauryssen, or any entity controlled by Lauryssen, currently practices medicine or contracts for services. 
  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 No provision under this Agreement, either overtly or covertly, directly or indirectly, requires or
contemplates that Lauryssen make any recommendations to Lauryssen’s patients or health care facilities with respect to Amedica’s Devices or other products. There shall be no adjustment to the percentage of royalties, or the rate of any
other compensation, if any, resulting from the presence of or absence of, any recommendations of Amedica’s Devices or other products to Lauryssen’s patients or health care facilities by Lauryssen. 
  
 If Lauryssen is paid any share of Net After Tax Profits inconsistent with the
provisions of this Subsection 5(d), upon advance written notice to Lauryssen, Amedica will offset such improperly paid amount from any future payment owing to Lauryssen. 
  
 e. Amedica shall maintain separate and sufficient accountings and records relating to the Devices to enable
the payments payable hereunder to be determined and verified. Lauryssen shall, at all times, have reasonable access to examine Amedica’s books and records relating to the Devices. The parties shall promptly reconcile any payment discrepancies
discovered through any such audit. 
  
 f. Without
limiting the provisions of Subsection 5(c), the parties acknowledge that the continued payment of, and the continuing obligation to pay, the royalties payable hereunder is not dependent on the continuing performance of the Development Services, the
ongoing Term of this Agreement, or any other contingency or condition. 
  
 g. Lauryssen acknowledges that the payment provisions of this Section 4 represent the sole agreement between the parties with regard to Lauryssen’s compensation for all Development Services and any
assignment of rights to the Devices; and Amedica shall not be obligated to make, or otherwise be liable for, any additional 

  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
payment of compensation or reimbursement of expenses with regard to Development Services or the Devices or other similar type payment. It is the
parties’ intent that this Agreement provide for the “sale or exchange of a capital asset” by Lauryssen to Amedica under Internal Revenue Code Section 1235 entitled “Sale or Exchange of Patents,” and that all payments
made to Lauryssen hereunder shall be taxed as long-term capital gains. Nothing in this Agreement to the contrary shall imply that the parties intend that the payments to Lauryssen hereunder shall be for anything other than the transfer of all
proprietary rights that Lauryssen may have in the Devices. Amedica is making no warranties or representations, however, as to ultimate taxability of the payments to Lauryssen hereunder. 
  
 6. Facilities. To the extent necessary, Amedica shall provide Lauryssen with office space, equipment,
telephone, secretarial help and all other equipment and related services necessary for the performance of the Development Services hereunder. 
  
 7. Exclusivity. Amedica acknowledges that Lauryssen, and any entities which may currently or in the future be controlled by Lauryssen, have
other professional business and investment dealings in addition to his responsibilities under this Agreement and that Lauryssen will not be required to devote his time exclusively to his responsibilities hereunder, either directly or indirectly.
Notwithstanding any provision herein to the contrary, Lauryssen agrees that during the Term, as between Lauryssen and Amedica, Amedica shall possess the exclusive ownership of the Devices. Amedica acknowledges that this is a non-exclusive agreement,
and nothing herein may be construed to prohibit either Amedica or Lauryssen from entering into similar contractual relationships with other parties, or from engaging or participating in any other venture, unrelated to the Devices. Without limiting
the foregoing, Amedica recognizes and 

  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
acknowledges that Lauryssen (either directly or though his entities) actively performs consulting and product development services for and on other parties
in the area of neurosurgery and related fields; therefore, Lauryssen may provide consulting, product development, and other services, not related to the Devices, for and on behalf of persons or entities that may compete with Amedica or that develop,
manufacture, or sell products or technologies that are similar in function or design (excluding the Field of Interest, which involves solely ceramic materials) to those developed or sold by Amedica. 
  
 8. Confidentiality. 
  
 a. Both during the Term and following termination of this
Agreement for any reason, except as necessary for the performance of the Development Services hereunder, Lauryssen shall not, at any time or in any manner, directly or indirectly, use, divulge, disclose or communicate to any third-person or entity
any information that was disclosed to or developed by Lauryssen during the course of performing the Development Services and which is not (i) information that Lauryssen was aware of prior to the term of this Agreement, (ii) information
that Lauryssen becomes aware of through a source other than Amedica, (iii) information that is available to the general public through a prior disclosure, provided that Lauryssen did not commit such prior disclosure in violation of this
Agreement, or (iv) the Retained Intellectual Property (as defined herein). Also without limiting the foregoing, Lauryssen may disclose the existence and general nature of this Agreement and the fact that it pertains to the Development Services
and the Devices. Subject to the foregoing exceptions, the confidential information described herein shall include information regarding matters affecting or relating to Amedica’s business or its Devices; the nature of Amedica’s properties
or products, whether 

  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
developed or under development; the identity of Amedica’s customers; prices which Amedica obtains or has obtained with respect to its products or
services; information as to Amedica’s discussions, negotiations and/or dealings with actual or potential third-party buyers, investors, licensees or co-venturers; Amedica’s costs, overhead or profit margin; or Amedica’s operational
methods or its business plans and processes. 
  
 b. Promptly following termination of this Agreement, Lauryssen shall deliver to Amedica any and all property of Amedica which may be in his possession including products, materials, memoranda, notes, records, reports, writings, drawings,
diskettes, models and other materials or other documents or photocopies of the same in any tangible form whatsoever constituting confidential or proprietary information of Amedica, and any of the foregoing in intangible form. 
  
 9. Covenant Not to Compete. 
  
 a. Lauryssen recognizes and acknowledges the competitive and
proprietary nature of Amedica’s Field of Interest. Lauryssen acknowledges and agrees that a business will be deemed competitive with Amedica if it develops, manufactures or sells any ceramic products within the Field of Interest and Lauryssen
has participated in the creation, research and/or testing of those such ceramic products (such business to be referred to as a “Competitive Business”). 
  
 b. Lauryssen agrees that during the Term and for an additional [*********] after termination of this
Agreement (which period shall be tolled during the period of any violation or breach of any of the provisions hereof and for a period of [**********] thereafter), whether such termination is voluntary or involuntary, Lauryssen shall not: 

 
 (i) for his benefit, or on behalf of any other person or
entity, directly or indirectly, as principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or control, or be concerned, connected or employed by, or otherwise associate in any manner with,
engage in or have a financial interest in any Competitive Business anywhere in the continental United States of America (the “Restricted Territory”), except that nothing contained herein shall preclude Lauryssen from purchasing or owning
securities of any such business if such securities are publicly traded, and provided that his holdings do not exceed one percent (1%) of the issued and outstanding securities of any class of securities of such business; or 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 (ii) either individually or on behalf of or through any third party, directly or
indirectly, solicit, entice or persuade or attempt to solicit, entice or persuade any other employees of or consultants to Amedica or any present or future parent, subsidiary or affiliate of Amedica to leave the services of Amedica or any such
parent, subsidiary or affiliate for any reason. 
  
 c. Lauryssen further recognizes and acknowledges that: (i) the restrictions in this Section 9 are reasonable in relation to the skills which represent his principal salable asset both to Amedica and to any prospective employers,
and (ii) the geographical scope of the provisions of this Section 9 is reasonable, legitimate and fair to Lauryssen in light of Amedica’s need to market its services and sell its products worldwide in order to have a sufficient
customer base to make Amedica’s business profitable and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which Lauryssen is qualified to earn his livelihood. 
  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 d. Notwithstanding anything herein to the contrary, nothing in this Section 9 shall
apply with regard to any services performed by Lauryssen prior to the Term hereof (and which services do not involve any activities by Lauryssen within the Field of Interest continuing from and after the date of this Agreement) with regard to any
devices, ideas, discoveries, creations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, processes, and materials of any kind (the “Prior Work”). Accordingly, nothing herein shall prohibit
Lauryssen’s receipt of any compensation of any kind (e.g., royalties) in consideration for such Prior Work. 
  
 e. The acknowledgments and agreements set forth in this Section 9 shall survive the termination of Lauryssen’s performance of
the Development Services for any reason, for the time period set forth herein. 
  
 10. Ownership of Ideas, Copyrights and Patents. 
  
 a. Lauryssen agrees that he will take reasonable steps to promptly disclose all Devices to Amedica and that he will not publish any
Devices, or any information with regard thereto, without the prior written consent of Amedica, which will not be unreasonably withheld. 
  
 b. As between Lauryssen and Amedica, Amedica shall have the sole and exclusive right, even as to Lauryssen, to prepare, file, prosecute,
obtain and maintain any and all patents and patent applications claiming any Devices. All Devices shall be the sole and exclusive property of Amedica and, subject to payment pursuant to the provisions of Section 3 hereof, and the waivers of any
and all representations and warranties concerning the Devices as set forth in Subsection 10(e) below, Lauryssen hereby assigns to Amedica all of his right, title and interest in and to all of the Devices, 

  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
including the intellectual property therein, which may include trade secrets, inventions, discoveries, or improvements, whether or not registerable or
patentable, that are conceived, whether alone or jointly with others, during the Term of this Agreement that are a direct and specific result of the Development Services (collectively, the “Assigned Intellectual Property”). This assignment
does not include any such intellectual property that pertains to: (i) neurosurgical principles in general (including products that may pertain to the same pathological conditions in the same anatomical locations that are relevant to the
Devices; to (ii) other products or technologies used in neurosurgery; (iii) to proprietary concepts and inventions in which Lauryssen has any right, title, or interest as of the date of the execution of this Agreement (collectively
“Prior Rights”), or (iv) to any other concept, know-how, discovery, or other intellectual property that is not within the definition of the Assigned Intellectual Property (all of the foregoing collectively, the “Retained
Intellectual Property”). Lauryssen shall not be restricted from assigning, licensing, or otherwise utilizing the Retained Intellectual Property in any manner. 
  
 c. Lauryssen hereby agrees to reasonably cooperate with Amedica, its attorneys and agents in the preparation
and filing of all papers and other documents as may be required to perfect Amedica’s rights in and to any Devices, including, but not limited to, performing all acts reasonably deemed necessary or desirable by Amedica (both during the Term and
for a period of [***********] after expiration of this Agreement) and joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States of America and of any and all other countries to Devices;
provided, that, Amedica will bear the expense of all such proceedings. Lauryssen hereby agrees that any patent or other legal right covering any Assigned Intellectual Property issued to Lauryssen, shall be assigned by Lauryssen to Amedica without
charge. 
  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 d. Without limiting the foregoing, Lauryssen further acknowledges that all original works
of authorship made by such Lauryssen, within the Field of Interest, by Lauryssen that Lauryssen has first conceived and first reduced to writing, whether alone or jointly with others during the Term of this Agreement that are a direct and specific
result of the Development Services and that are protectable by copyright are “works made for hire” within the meaning of the United States Copyright Act, 17 U.S.C. § 101, as amended, the copyright of which shall be owned solely,
completely and exclusively by Amedica. If any such work is not considered to be a work made for hire covered by the United States Copyright Act, 17 U.S.C. § 101, as amended, such work shall be owned solely by, or hereby assigned or transferred
completely and exclusively to, Amedica. Any and all works of authorship described in this Subsection shall be included within the definition of Assigned Intellectual Property. 
  
 e. Notwithstanding anything herein to the contrary, Lauryssen expressly disclaims, and Amedica expressly
waives, any and all representations and warranties in regard to or concerning the Assigned Intellectual Property, the Development Services and the Devices. Without limiting the foregoing, the parties agree that Lauryssen does not represent or
warrant that any portion of the Assigned Intellectual Property is valid, enforceable, registerable, or original, that it will be free from claims of infringement, interference, or unlawful use of proprietary information of any third party, or that
it does not infringe upon the intellectual property rights of any other party. Furthermore, Lauryssen expressly disclaims, and Amedica expressly waives, the warranties of 

  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
merchantability and fitness for a particular purpose with regard to the Assigned Intellectual Property, the Development Services and the Devices, and any and
all representations and warranties that the Assigned Intellectual Property and the Devices will perform or function in any particular manner, with any particular results, or free from defects. 
  
 11. Representations and Warranties Regarding Prior Work and Legal
Obligations. 
  
 a. Lauryssen hereby
represents and warrants that he has no commitments or obligations with any prior employer or any other person or entity that, would restrict his ability to perform the Development Services. 
  
 b. Lauryssen represents that he has been advised by Amedica
that at no time should he divulge to, or use for the benefit of, Amedica any trade secret or confidential or proprietary information of any previous employer. Lauryssen acknowledges that he has not divulged or used any such information for the
benefit of Amedica. 
  
 c. Lauryssen acknowledges
that Amedica is basing important business decisions on these representations, and affirms that all of the statements included herein are true. 
  
 12. Equitable Remedies. Lauryssen acknowledges that the breach of the provisions of Sections 8, 9, 10 and 11 above shall constitute
irreparable damage to Amedica and, accordingly, Amedica may, in addition to all other available remedies under law and equity, obtain injunctive relief upon an alleged violation of such Sections pending resolution on the merits of any claims raised
by Amedica hereunder. 
  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 13. Stock Option Arrangements. As further consideration hereunder, the parties agree in
good faith to negotiate an agreement granting Lauryssen, or Lauryssen’s designate, certain rights to obtain options for the purchase of Amedica stock. The nature, amount and terms of such options shall be agreed upon by the parties in
good-faith as soon as reasonably possible. 
  
 14.
Development Agreement Only. This Agreement constitutes a development agreement only. Nothing herein is intended, nor shall it be construed, to create any employer/ employee arrangement, partnership arrangement or other relationship
between or among the parties except as expressly provided herein; and nothing herein is intended to grant to either party any right or interest in or to the assets, business or interests of the other party, nor the right to bind the other party
except as expressly herein provided. 
  
 15. Compliance with
Laws and Regulations. The parties, at all times, shall interpret and apply the provisions of this Agreement strictly in accordance with all applicable laws and regulations, including, but not limited to all Medicare and Medicaid laws and
regulations. 
  
 If any provision of this Agreement is found, by
any applicable court or government agency, to be in conflict with any applicable law or regulation, the provisions of such law or regulation shall govern; and the interpretation and operation under this Agreement shall be modified accordingly.

  
 The parties have no intent through this Agreement or otherwise
to solicit, receive, offer, or pay any remuneration in return for recommending the use or utilization of any good or service payable under certain federal health programs, as such is prohibited by the statute at 42 U.S.C. 1320a-7b(b), nor do the
parties have any other impermissible intent to violate any similar federal or state law that may apply with regard to any other health care reimbursement program. 

  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
Lauryssen is under no obligation whatsoever to utilize any products manufactured by Amedica, nor to recommend that such products are utilized by others. If
any provision of this Agreement is determined by either party to present a possible violation of any such law, as supported by a written, reasoned opinion of competent legal counsel, the parties shall in good faith negotiate together to amend the
terms of this Agreement in a manner that will alleviate any such possible violation while preserving the reasonable business (e.g., compensation) expectations of the parties. 
  
 16. Indemnification by Amedica. 
  
 a. Amedica will indemnify and hold Lauryssen harmless from any and all claims, costs, judgments and expenses
involving (i) any claim that any Device infringes or interferes with any patent or other proprietary claim of any third-party, and (ii) to the extent claimed or proven to be solely due to Device design or manufacturing defect (including
reasonable attorneys’ fees) of whatever sort based on claims of product design or manufacturing defects whether sounding in negligence, strict liability at law, contract or statutory violation, and (iii) any breach by Amedica of any
provision of this Agreement. 
  
 b. Any
indemnification provided by Amedica hereunder shall not apply to any claim insofar as that claim (i) relates to a professional medical liability or malpractice claim brought against Lauryssen for professional acts or omissions in connection
with the medical care or treatment associated with a Device; (ii) arises from any breach by Lauryssen of any provision of this Agreements; or (iii) arises from any knowing submission by Lauryssen of false data to Amedica or from any other
intentional wrongdoing by Lauryssen. 
  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 c. Promptly upon Lauryssen’s receipt of information concerning the commencement of
any third-party claim, demand, action, suit or proceeding (collectively, “Action”) which is the subject of indemnification hereunder, Lauryssen shall notify Amedica in writing of the commencement of the Action. Any failure to provide such
prompt notice shall relieve Amedica of its indemnification obligations to the extent Amedica has been materially prejudiced by such failure. Amedica may select counsel at its own expense and control the defense of such indemnity claim; and Lauryssen
may participate jointly with Amedica in such defense, at Lauryssen’s expense, in which event the parties shall reasonably cooperate with each other. Amedica will vigorously defend any such claim, and shall not settle any such claim or refrain
from appealing any adverse ruling, judgment, or verdict without the advance written consent of Lauryssen, which consent shall not be unreasonably withheld. With respect to any Action relating solely to the payment of money damages, Amedica shall
have the sole right to defend, settle, or otherwise dispose of such claim on such terms as Amedica, in its sole discretion, shall deem appropriate; provided, that Amedica shall provide reasonable evidence of its ability to pay any damages claimed.
If the Action involves any claim in which Lauryssen would become subject to injunctive relief or to other equitable relief, or Lauryssen’s business would be adversely affected in any manner, Amedica shall settle that claim only upon the written
consent of Lauryssen, which shall not be unreasonably withheld. 
  
 17. Indemnification by Lauryssen. Except to the extent that any such claims arise through the wrongful act or neglect of Amedica, Lauryssen will indemnify and hold Amedica harmless from any and all claims, costs, judgments and
expenses arising from any breach by Lauryssen of any warranty, representation or affirmative obligation of Lauryssen under this Agreement. 
  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 18. General. 
  
 a. Notices. All notices required or permitted to be given to a party hereunder shall be mailed by
certified mail or registered mail, postage prepaid, to that party’s address set forth on the signature page of this Agreement (or to such other address specified in writing). 
  
 b. Default. If either party defaults in any of the covenants or provisions herein, the defaulting
party shall pay all costs and attorneys’ fees incurred by the other party in enforcing its rights arising hereunder. Lauryssen’s counsel set forth below shall be provided with a copy of any notice given to Lauryssen hereunder: 

 
 Thad N. Leach 
 Lewis, Rice & Fingersh, L.C. 
 500 N. Broadway, Suite 2000 
 St. Lewis, Missouri 63102 
  
 c. Governing Law and Venue. This Agreement shall be interpreted, performed and enforced according to the laws of Utah. Venue for
any action hereof shall lie with the Third Judicial District Court of the State of Utah for the United States District Court for the District of Utah, Central Division. 
  
 d. Unenforceable Provision. If any provision of this Agreement is deemed unenforceable by any court
of competent jurisdiction, the remaining provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be over broad as written, such provision shall be deemed amended to narrow its application to the
extent necessary to make the provision enforceable according to applicable law and shall be enforced as amended. 
  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 e. Assignment. Amedica may assign its rights and obligations hereunder to any
person or entity that succeeds to all or substantially all of Amedica’s business or that aspect of Amedica’s business in which Lauryssen is principally involved. Lauryssen’s rights and obligations under this Agreement may not be
assigned by that Lauryssen without the prior written consent of Amedica. 
  
 f. Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and
permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except between the parties hereto, and no person or entity shall be regarded as a third-party beneficiary of this Agreement,
other than any future parent, subsidiary or affiliate of Amedica. 
  
 g. Entire Agreement. This Agreement embodies the entire agreement and understanding between and among the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written
agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the
express terms and provisions of this Agreement. 
  
 h. Modifications and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto. 
  
 i. Waivers and Consents. The terms and provisions of this Agreement may be waived, or consent for the
departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver 

  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 
or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not
similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent. 
  
 j. Construction. The parties have participated equally in the formation of this Agreement and the
language of this Agreement will not be presumptively construed against either party. 
  
 k. Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 l. Section Numbers and Headings. The Section and Subsection headings and numbers used herein are for purposes of convenience and
shall not be considered in the interpretation of this Agreement. 
  
 IN WITNESS WHEREOF this 17th day of August, 2005. 
  

							
		 		 	AMEDICA
			
	 ADDRESS:
	 		 	 AMEDICA CORP.
 A DELAWARE CORPORATION

			
	 Amedica Corporation
	 		 	
	 615 Arapeen Drive, Suite 302
	 		 	By	 	 /s/ Ashok Khandkar

	 Salt Lake City, UT 84108
	 		 	Its:	 	President and CEO
			
		 		 	LAURYSSEN
			
	 ADDRESS:
	 		 	
			
	 Carl Lauryssen, M.D.
	 		 	
	 [********************]
	 		 	 /s/ Carl Lauryssen, M.D.

	 [********************]
	 		 	CARL LAURYSSEN, M.D.

  

 20 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE A 
  

Devices 
  
 The Devices consist of the following: 
  

	 	1.	 	[**************] 

  

	 	2.	 	[**************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended. 

 SCHEDULE B 
  

List of Collaborators 
  

	[1]	 	[**************] 

  

	[2]	 	[**************] 

  

	[3]	 	[**************], and 

  

	[4]	 	[**************] 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]